SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lei Liu, Carina Peritore, Jessica Ginsberg, Jennifer Shih, Siddharth Arun, Gizem Donmez, Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease, Behavioural Brain Research, 2015, 281, 215

    CrossRef

  2. 2
    Roy Lardenoije, Artemis Iatrou, Gunter Kenis, Konstantinos Kompotis, Harry W.M. Steinbusch, Diego Mastroeni, Paul Coleman, Cynthia A. Lemere, Patrick R. Hof, Daniel L.A. van den Hove, Bart P.F. Rutten, The epigenetics of aging and neurodegeneration, Progress in Neurobiology, 2015, 131, 21

    CrossRef

  3. 3
    Jacinth Naidoo, Hector De Jesus-Cortes, Paula Huntington, Sandi Estill, Lorraine K. Morlock, Ruth Starwalt, Thomas J. Mangano, Noelle S. Williams, Andrew A. Pieper, Joseph M. Ready, Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(−)-P7C3-S243], with Improved Druglike Properties, Journal of Medicinal Chemistry, 2014, 57, 9, 3746

    CrossRef

  4. 4
    Andrew A. Pieper, Steven L. McKnight, Joseph M. Ready, P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases, Chem. Soc. Rev., 2014, 43, 19, 6716

    CrossRef

  5. 5
    Navneet Ammal Kaidery, Shaista Tarannum, Bobby Thomas, Epigenetic Landscape of Parkinson’s Disease: Emerging Role in Disease Mechanisms and Therapeutic Modalities, Neurotherapeutics, 2013, 10, 4, 698

    CrossRef

  6. 6
    Ingrid H. C. H. M. Philippens, Jacqueline A. Wubben, Bente Finsen, Bert A. ‘t Hart, Oral Treatment with the NADPH Oxidase Antagonist Apocynin Mitigates Clinical and Pathological Features of Parkinsonism in the MPTP marmoset Model, Journal of Neuroimmune Pharmacology, 2013, 8, 3, 715

    CrossRef

  7. 7
    James M. Flynn, Simon Melov, SOD2 in mitochondrial dysfunction and neurodegeneration, Free Radical Biology and Medicine, 2013, 62, 4

    CrossRef

  8. 8
    Hanna S. Lindgren, Stephen B. Dunnett, Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models?, European Journal of Neuroscience, 2012, 35, 12
  9. 9
    H. De Jesus-Cortes, P. Xu, J. Drawbridge, S. J. Estill, P. Huntington, S. Tran, J. Britt, R. Tesla, L. Morlock, J. Naidoo, L. M. Melito, G. Wang, N. S. Williams, J. M. Ready, S. L. McKnight, A. A. Pieper, Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease, Proceedings of the National Academy of Sciences, 2012, 109, 42, 17010

    CrossRef

  10. 10
    Mi Jin Kim, Dae Won Kim, Hoon Jae Jeong, Eun Jeong Sohn, Min Jea Shin, Eun Hee Ahn, Soon Won Kwon, Young Nam Kim, Duk-Soo Kim, Jinseu Park, Won Sik Eum, Hyun Sook Hwang, Soo Young Choi, Tat-Frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson's disease, Biochimie, 2012, 94, 11, 2448

    CrossRef

  11. 11
    Mee Sook Hong, Hun-Kuk Park, Jong-Soo Yang, Hi-Joon Park, Seung-Tae Kim, Seung-Nam Kim, Ji-Yeun Park, Jeong Yoon Song, Hyun-Kyung Park, Dae Jean Jo, Sung Wook Park, Dong HwanYun, Ju Yeon Ban, Joo-Ho Chung, Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model, Neurological Research, 2010, 32, Supplement-1, 74

    CrossRef

  12. 12
    J.R. Cashman, M.S. Motika, Comprehensive Toxicology, 2010,

    CrossRef

  13. 13
    Stefanie L. Byler, Gary W. Boehm, Jonathan D. Karp, Rachel A. Kohman, Andrew J. Tarr, Timothy Schallert, Timothy M. Barth, Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice, Behavioural Brain Research, 2009, 198, 2, 434

    CrossRef

  14. 14
    Principles of Biochemical Toxicology, Fourth Edition, 2008,

    CrossRef

  15. 15
    Elizabeth Knyihár-Csillik, Zoltan Chadaide, András Mihály, Beata Krisztin-Péva, Robert Fenyő, László Vécsei, Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra, Acta Neuropathologica, 2006, 112, 2, 127

    CrossRef

  16. 16
    Katarzyna Ulanowska, Jacek Piosik, Anna Gwizdek-Wiśniewska, Grzegorz We¸grzyn, Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin, Bioorganic Chemistry, 2005, 33, 5, 402

    CrossRef

  17. 17
    M. G. Kadieva, E. T. Oganesyan, S. Kh. Mutsueva, Neurotoxins and Drugs for the Treatment of Parkinson's Disease. Part I: Neurotoxins, Levodopa, and Agents Influencing Dopamine Metabolism (A Review), Pharmaceutical Chemistry Journal, 2005, 39, 9, 453

    CrossRef

  18. 18
    Heike Endepols, Johannes Schul, H. Carl Gerhardt, Wolfgang Walkowiak, 6-hydroxydopamine lesions in anuran amphibians: A new model system for Parkinson's disease?, Journal of Neurobiology, 2004, 60, 4
  19. 19
    Werner J Geldenhuys, Sarel F Malan, Thangaraju Murugesan, Cornelis J Van der Schyf, Jeffrey R Bloomquist, Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease, Bioorganic & Medicinal Chemistry, 2004, 12, 7, 1799

    CrossRef

  20. 20
    Mark Noble, The possible role of myelin destruction as a precipitating event in Alzheimer’s disease, Neurobiology of Aging, 2004, 25, 1, 25

    CrossRef

  21. 21
    1-Methyl-4-phenyl-1,2,5,6-Tetrahydropyridine (MPTP),